Results of Operations and Financial Condition. On August 13, 2026, Pulmatrix, Inc. issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2026, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02…

Results of Operations and Financial Condition. On May 15, 2026, Pulmatrix, Inc. issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2026, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02, s…

Other Events On April 16, 2026, the Company closed its previously announced private placement of its Series B Preferred Stock, par value $0.0001 per share (the “ Private Placement ”). The Private Placement was exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions…

Entry into a Material Definitive Agreement. Merger Agreement On March 26, 2026, Pulmatrix, Inc., a Delaware corporation (“ Pulmatrix ” or the “ Company ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”), by and among Pulmatrix, PUOS Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Pulmatrix (“ Merger Sub ”) and Eos SENOLYTIX, Inc., a Delaware corporation (“ Eos ”), pursuant to which, and subject to the satisfaction or waiver…

Regulation FD Disclosure. On March 26, 2026, Pulmatrix and Eos issued a joint press release announcing the execution of the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for p…

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in

Changes in Control of Registrant. To the extent required by this Item, the information included in

Material Modification to Rights of Security Holders. To the extent required by this Item, the information included in

Termination of a Material Definitive Agreement. On February 28, 2026, Pulmatrix, Inc. (the “ Company ” or “ Pulmatrix ”) received a termination notice (the “ Notice ”) from Cullgen Inc. (“ Cullgen ”) pursuant to which Cullgen informed the Company that in accordance with Sections 11.7 and 10.1(b) of that certain Agreement and Plan of Merger and Reorganization, dated as of November 13, 2024, as amended by Amendment No. 1 thereto dated as of April 7, 2025 (the “ Merger Agreement ”), by and among…

Results of Operations and Financial Condition. On February 26, 2026, Pulmatrix, Inc. issued a press release announcing its financial results for the fourth fiscal quarter and the twelve months ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02, sha…

Results of Operations and Financial Condition. On October 16, 2025, Pulmatrix, Inc. issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2025, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item…

Results of Operations and Financial Condition. On August 6, 2025, Pulmatrix, Inc. issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2025, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02,…

Other Events. CSRC Completion of the Merger is subject to receipt of required regulatory approvals, including approval from the China Securities Regulatory Commission (the “CSRC”) pursuant to the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises (the “Trial Measures”), No. 1 to No. 6 Supporting Guidance Rules, the Notice on Administration Arrangements for the Filing of Overseas Listings by Domestic Enterprises and the relevant CSRC Answers to Re…

Results of Operations and Financial Condition. On May 15, 2025, Pulmatrix, Inc. issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2025, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02, s…

Changes in Control of Registrant. To the extent required by this Item, the information included in

of this Current Report on Form 8-K is incorporated herein by reference. Forward-Looking Statements This Current Report on Form 8-K and the exhibits filed or furnished herewith contain forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”)) concerning Pulmatrix, Cullgen, the proposed transactions and other matters. These forwa…

Results of Operations and Financial Condition. On March 21, 2025, Pulmatrix, Inc. issued a press release announcing its financial results for the fourth fiscal quarter and the twelve months ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02, shall…

The excerpt does not provide specific details about a management change, compensation arrangement, or any other material event.

Regulation FD Disclosure. On November 13, 2024, Pulmatrix and Cullgen issued a joint press release announcing the execution of the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference. Furnished as Exhibit 99.2 hereto and incorporated herein by reference is the investor presentation th…

Entry into a Material Definitive Agreement. Merger Agreement On November 13, 2024, Pulmatrix, Inc., a Delaware corporation (“Pulmatrix”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), by and among Pulmatrix, PCL Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Pulmatrix (“Merger Sub I”), PCL Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Pulmatrix (“Merger Sub II” and together with…

Changes in Control of Registrant. To the extent required by this Item, the information included in

Results of Operations and Financial Condition. On November 8, 2024, Pulmatrix, Inc. issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2024, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item…

Results of Operations and Financial Condition. On August 13, 2024, Pulmatrix, Inc. issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2024, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02…

CEO — Teofilo Raad: Mr. Teofilo Raad's employment with the company has ceased, and he is receiving a severance package.

Entry into a Material Definitive Agreement. On May 28, 2024, Pulmatrix, Inc. (the “ Company ”) and MannKind Corporation, a Delaware Corporation (“ MannKind ”) entered into a Bill of Sale and Assignment Agreement (the “ BSA ”) with respect to the transfer of the Company’s Bedford, Massachusetts, R&D facility (the “ R&D Facility ”) to MannKind along with all leasehold improvements, laboratory equipment and other related personal property. In connection with the transfer of the R&D Facility, the…